
A meta-analysis evaluating fezolinetant's efficacy for menopausal vasomotor symptoms (VMS) included five randomized clinical trials with 2,168 participants. Fezolinetant significantly reduced VMS frequency and improved sleep quality compared to placebo, with a pooled mean difference of 2.62 for VMS frequency and a mean percentage improvement of 22.51%. The Menopause-Specific Quality of Life measure showed a pooled mean difference of -0.60. The findings suggest fezolinetant as an effective treatment for moderate-to-severe VMS and associated sleep disturbances in postmenopausal women.
Like
Save
Share